| Autor: |
Chiho Nakashima, Yuki Kuwahara, Syo Kitamura, Keita Kai, Masafumi Hiratsuka, Kokoro Kajiwara, Natsuko Komiya, Shinsuke Ogusu, Shinya Kimura, Naoko Sueoka-Aragane |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Current Problems in Cancer: Case Reports, Vol 14, Iss , Pp 100298- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6219 |
| DOI: |
10.1016/j.cpccr.2024.100298 |
| Popis: |
Immune checkpoint inhibitors (ICIs) are indispensable agents that may improve the long-term prognosis of non-small cell lung cancer. However, clinicians should always be aware that its immune-modulating mechanism of action may lead to unexpected immune-related adverse events (irAE). We report here a case of a 72-year-old man with adenocarcinoma of the lung who achieved a complete response to nivolumab plus ipilimumab plus chemotherapy but also suffered from a variety of immune-related adverse events. In this patient, Th1 immunity, which is involved in antitumor immunity, and Th2 immunity were activated, resulting in allergy-related reactions, including increased airway hyperresponsiveness and a marked increase in serum IgE levels. After starting corticosteroids, the allergic symptoms were well controlled. Remarkably, despite discontinuing ICI treatment, the patient has maintained a complete response for 27 months. Fortunately, we obtained lung and lymph node tissues from this patient after ICI administration and histologically examined the Th1 and Th2 immune status. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
